Results 41 to 50 of about 57,366 (267)

Attenuation of Influenza a Virus into Live Vaccines Through C‐End Degrons

open access: yesAdvanced Science, EarlyView.
Naturally occurring C‐end degrons are exploited to design proteolysis‐targeting live attenuated influenza vaccines. C‐end degron tagging of viral M1 protein promotes proteasome‐dependent degradation, resulting in robust attenuation in host cells while permitting scalable production in engineered cells.
Ping Wang   +14 more
wiley   +1 more source

RNF213 Is an Interferon‐Stimulated Gene That Targets Influenza A Virus NP and Activates MDA5 to Restrict Infection

open access: yesAdvanced Science, EarlyView.
RNF213 is characterized as a dual‐functional antiviral effector. It directly mediates the degradation of the influenza A virus nucleoprotein (NP) while simultaneously activating the MDA5‐mediated innate immune signaling pathway. This coordinated response establishes a powerful host defense system against viral infection. ABSTRACT Influenza A virus (IAV)
Haoning Li   +5 more
wiley   +1 more source

Intranasal fentanyl for pain control: current status with a focus on patient considerations

open access: yesPatient Preference and Adherence, 2011
Eric Prommer, Lisa ThompsonDivision of Hematology/Oncology, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Scottsdale, AZ, USAAbstract: Of several newer delivery systems under development and investigation for the administration of opioids, the ...
Eric Prommer, Lisa Thompson
doaj  

Intranasal administration of gentamicin in human subjects [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 1983
The effectiveness of gentamicin administered by the intranasal route in healthy human volunteers was studied. Thirty minutes after gentamicin in a solution of 1% sodium glycocholate was administered at 2 mg/kg of body weight, gentamicin concentrations of 2.48 +/- 0.42 mg/ml were present in the sera. Serum concentrations decreased to 0.94 +/- 0.13 mg/ml
openaire   +2 more sources

Endogenous “Time Bomb” – Mislocalized Phospholipase A2 as a Critical Mediator of Ultra‐Rapid Mortality in Sepsis and Acute Lung Injury

open access: yesAdvanced Science, EarlyView.
Phospholipase A2 (PLA2), a dormant enzyme, becomes lethal when activated—collapsing lungs in minutes. Our dual therapy (DOPS + varespladib) boosts survival from 0% to >90% in sepsis/ALI. A breakthrough for acute lung injury treatment. ABSTRACT This study reveals that phospholipase A2 (PLA2), normally stable and nontoxic, can be activated specifically ...
Jianyu Wang   +7 more
wiley   +1 more source

Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats

open access: yesFrontiers in Aging Neuroscience, 2020
Cognitive function represents a key determinative factor for independent functioning among the elderly, especially among those with age-related cognitive disorders.
Coleman B. Calva   +2 more
doaj   +1 more source

Neuid: A Novel Neuron‐Enriched LncRNA that Connects Epigenetic Gene Silencing to Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
ABSTRACT The increasing evidence that non‐coding RNAs can become deregulated during pathogenesis is dramatically expanding the space for drug discovery beyond the protein‐coding genome. Long noncoding RNAs (lncRNAs) are emerging as key regulators of cellular function, yet most remain uncharacterized.
Ranjit Pradhan   +17 more
wiley   +1 more source

Biomimetic Ru‐Mn Nanozyme with Cascade Catalytic Activity Attenuates Secondary Brain Injury in Intracerebral Hemorrhage

open access: yesAdvanced Science, EarlyView.
Ru–Mn composite nanozymes are engineered to mimic dual‐enzyme cascade catalysis, enabling efficient ROS clearance and neuroinflammation suppression. In collagenase‐ and autologous blood‐induced ICH mouse models, intranasal and intravenous administration reduced hematoma volume, preserved BBB integrity, and improved neurological recovery.
Zhongxin Duan   +8 more
wiley   +1 more source

A NeuroD1 AAV‐Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease‐Like Non‐Human Primate Model

open access: yesAdvanced Science, EarlyView.
This study tests NeuroD1 AAV‐based gene therapy in a non‐human primate Alzheimer's disease model. The therapy prevents neuronal damage, inhibits hippocampal atrophy, and reduces neuroinflammation. It also repairs vascular and blood‐brain barrier damage, restores cerebrospinal fluid biomarkers, enhances hippocampal glucose metabolism, and improves ...
Zhouquan Jiang   +21 more
wiley   +1 more source

AAV vector distribution in the mouse respiratory tract following four different methods of administration

open access: yesBMC Biotechnology, 2017
Background Targeted delivery of gene therapy vectors to the mouse respiratory tract is often performed via intranasal or intratracheal administration; however, there can be a great deal of variability between these methods, which could potentially ...
Lisa A. Santry   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy